Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS

Neurol Neuroimmunol Neuroinflamm
01 Oct 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204226/#:~:text=Advocates%20of%20LDN%20use%20have,increased%20risk%20of%20developing%20ITP

What to know about LDN for rheumatoid arthritis

Medical News Today
21 June 2022
https://www.medicalnewstoday.com/articles/ldn-for-rheumatoid-arthritis

Low dose naltrexone (LDN) is a medication. Some researchers believe LDN can help with autoimmune diseases, such as multiple sclerosis, Crohn’s disease, and psoriasis. For this reason, some scientists have looked into the potential efficacy of LDN in treating rheumatoid arthritis (RA). 

LDN Webinar Presentation 18 May 2022: Dr Masoud Rashidi - LDN, Dosing, Fillers and Compounded Options. LDN, ULDN and Pain/Opioid Issues

Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/

LDN Webinar 18 May 2022 (LDN; low dose naltrexone)

LDN Questions Answered Live by

Pharmacist Dr Masoud Rashidi - LDN Specialist
Dr Sato-Re
Dr Mathewson

Sponsored by Innovative Compounding Pharmacy icpfolsom.com

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study

BMJ Open
08 April 2022
https://pubmed.ncbi.nlm.nih.gov/35396307/

Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

GlobalNewswire
27 April 2022
https://www.globenewswire.com/news-release/2022/04/27/2430707/0/en/Statera-Biopharma-and-Immune-Therapeutics-Inc-Announce-Strategic-Agreement-for-Rights-to-Low-Dose-Naltrexone.html